Keck School Faculty

Liyun Yuan

Liyun Yuan

Assistant Professor of Clinical Medicine
HCC 261 1510 San Pablo Street Mail Code:9198 Health Sciences Campus Los Angeles


American Association of Pharmaceutical Sciences: Graduate Student Award, 2006

: Charles and Charlotte Krown Fellowship, 2005

Rho Chi Pharmacy Honor Society: Member, 2004

Bile acid receptors and nonalcoholic fatty liver disease World J Hepatol. 2015 Dec 08; 7(28):2811-8. . View in PubMed

Mechanisms of drug-induced liver injury Clin Liver Dis. 2013 Nov; 17(4):507-18vii. . View in PubMed

Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria Trends Pharmacol Sci. 2013 Apr; 34(4):243-53. . View in PubMed

Glutathione in liver diseases and hepatotoxicity Mol Aspects Med. 2009 Feb-Apr; 30(1-2):29-41. . View in PubMed

Reversible lipidization of somatostatin analogues for the liver targeting Eur J Pharm Biopharm. 2008 Oct; 70(2):615-20. . View in PubMed

Lipidization of human interferon-alpha: a new approach toward improving the delivery of protein drugs J Control Release. 2008 Jul 02; 129(1):11-7. . View in PubMed

Reversible lipidization prolongs the pharmacological effect, plasma duration, and liver retention of octreotide Pharm Res. 2005 Feb; 22(2):220-7. . View in PubMed

Dr. Yuan is a transplant hepatologist specializing in caring for patients with chronic liver diseases, hepatocellular carcinoma, and pre-/post liver transplantation. She completed her internship and residency training in Internal Medicine at Keck USC School of Medicine, where she further finished gastroenterology fellowship training. After that, she took an extra year advanced training in transplant hepatology at University of Colorado, Denver.

Dr. Yuan’s clinical research interests include Nonalcoholic fatty liver disease, autoimmune hepatitis and outcome of liver transplantation. She has authored several articles in peer-reviewed journals on various topics in liver disease and liver transplantation. Dr. Yuan's research activities include searching and validating diagnostic markers and prognostic makers in nonalcoholic steatohepatitis, liver targeting of anti-fibrotic therapy, and the role of PGAM5 in hepatic cell death- using the model of acetoaminophen-induced liver injury.
sc ctsi logoPowered by SC CTSI